[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368909-105":59,"doc-detail-368909-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","added-value-of-3-deoxy-3-18ffluorothymidine-positron-emission-tomography-for-response-assessment-in-patients-with-head-and-neck-cancer-a-systematic-review","Added value of 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography for response assessment in patients with head and neck cancer - a systematic review","","Current tools for evaluating head and neck cancer (HNC) therapy response are limited by heterogeneous tumor representation, biopsy-related complications, and delayed assessment due to late anti-cancer effects. This systematic review examines whether positron emission tomography using 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT-PET) can provide an accurate, timely measure of treatment response. Searches of Medline and Embase assessed links between tumor [18F]FLT uptake and clinical outcomes. Eight studies (225 patients) showed early [18F]FLT uptake reduction after therapy, and two comparative studies (58 patients) found lower post-therapy [18F]FLT uptake than [18F]FDG uptake. Correlations with local control and survival endpoints were reported in multiple studies, supporting [18F]FLT-PET as a reliable response assessment tool.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/added-value-of-3-deoxy-3-18ffluorothymidine-positron-emission-tomography-for-response-assessment-in-patients-with-head-and-neck-cancer-a-systematic-review/368909/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/added-value-of-3-deoxy-3-18ffluorothymidine-positron-emission-tomography-for-response-assessment-in-patients-with-head-and-neck-cancer-a-systematic-review/368909.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are existing therapy response tools limited in head and neck cancer?","Question",{"text":112,"@type":113},"They can inadequately represent heterogeneous tumors, may involve complications from biopsy collection, and often lead to delayed evaluation due to late anti-cancer effects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the systematic review find about [18F]FLT-PET after therapy?",{"text":117,"@type":113},"Eight studies totaling 225 patients showed a significant reduction in [18F]FLT uptake early after therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How does [18F]FLT-PET compare with [18F]FDG-PET for response assessment?",{"text":121,"@type":113},"Two comparative studies with 58 patients showed that post-therapy [18F]FLT-PET uptake was significantly lower than post-therapy [18F]FDG uptake in HNC patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368909,1790782270,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","AnnAls of Medicine  \n2025, Vol. 57, no. 1, 2572311  \n[https://doi.org/10.1080/07853890.2025.2572311](https://doi.org/10.1080/07853890.2025.2572311)  \nRESEARCH ARTICLE     \nAdded value of 3′-deoxy-3′-[ 18F]fluorothymidine-positron emission tomography for response assessment in patients with head and neck cancer: a systematic review  \nBandar Alwadania , Louy Nammazia, Osama Suwaydia, Ziyad Faqiha, Abdullah Agilya, Omar Abdalib, Mozdalifah Elnaeema, Ali S. Alyamia , Yahia Madkhalia, Wael Ageelia , Turkey Refaeea and Naif Majrashia  \nadiagnostic Radiography Technology (dRT) department, college of nursing and Health sciences, Jazan University, Jazan, saudi Arabia; bKing Abdulaziz Hospital, Jeddah, saudi Arabia  \nABSTRACT  \nBackground and purpose: Current tools for evaluating therapy response in head and neck cancer (HNC) have multiple limitations, such as poor representation of heterogeneous tumours, potential complications associated with biopsy collection, and late anti-cancer effects on tumour, leading to delayed evaluation. Therefore, an accurate tool that can assess early therapy response in HNC patients is urgently needed. Positron emission tomography using 3′-deoxy-3′-[ 18F]fluorothymidine ([18F]FLT-PET) has exhibited preliminary promising roles in measuring therapy response in HNC. This systematic review explores the role of [ 18F]FLT-PET imaging in assessing treatment response in HNC patients.  \nMaterials and methods: Medline and Embase databases via Ovid interface were searched on the basis of the search strategy and selection criteria. Evidence linking the tumour uptake of [ 18F]FLT-PET with the outcomes of HNC patients was evaluated. Results: Ultimately, eight studies comprising 225 patients showed significant reduction of [ 18F]FLT uptake early after therapy. Also, two comparative studies that included 58 patients exhibited that post-therapy [ 18F]FLT-PET uptake was significantly lower than post-therapy [ 18F]fluorodeoxyglucose ([18F]FDG) uptake in HNC patients. [ 18F]FLT displayed significant correlation with different clinical endpoints, including local control, disease-free survival and overall survival in four studies, including 123 patients. Conclusions: [ 18F]FLT-PET seems to be an accurate and timely tool for assessing therapy response in HNC patients.  \nIntroduction  \nARTICLE HISTORY  \nReceived 20 February 2025  \nAccepted 25 September 2025  \nKEYWORDS  \n[ 18F]FLT; cell proliferation; positron emission tomography; head and neck cancer; therapy response; imaging biomarker  \nHead and neck cancer (HNC) ranks seventh among cancers with the highest incidence worldwide, leading to about 5% of all cancer-related deaths [1] . It is the ninth most common cancer in the Kingdom of Saudi Arabia [2] . It is more prevalent in the southwest region of Saudi Arabia than in other regions of the country, and Jazan Province in particular has the highest incidence rate of HNC in Saudi Arabia [3] .  \nA set of protocols for HNC management is followed. In the early stages of the disease, surgery and radiotherapy are the primary treatment options, except in cases such as lip cancer and soft palate where surgery may not be feasible. In such cases, radiotherapy alone is considered the first-line treatment option. In advanced stages of HNC, chemotherapy is the first-line treatment [4] .  \nThe traditional method of evaluating therapy response to cancer treatment is by assessing tumour size using computed tomography (CT) imaging. However, tumour shrinkage may not be detectable for weeks or even months from treatment initiation. Therefore, finding biomarkers that can assist in  \nCONTACT Bandar Alwadani  [balwadani@jazanu.edu.sa](balwadani@jazanu.edu.sa)  diagnostic Radiography Technology (dRT) department, college of nursing and Health sciences, Jazan University, Jazan, saudi Arabia  \n supplemental data for this article can be accessed online at [https://doi.org/10.1080/07853890.2025.2572311](https://doi.org/10.1080/07853890.2025.2572311) .  \n©","cbCaitRoE8G1aHkw","https://ap.wps.com/l/cbCaitRoE8G1aHkw","pdf",853986,"English","# Abstract\n# Introduction\n# Materials and methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"Why are existing therapy response tools limited in head and neck cancer?\",\"answer\":\"They can inadequately represent heterogeneous tumors, may involve complications from biopsy collection, and often lead to delayed evaluation due to late anti-cancer effects.\"},{\"question\":\"What did the systematic review find about [18F]FLT-PET after therapy?\",\"answer\":\"Eight studies totaling 225 patients showed a significant reduction in [18F]FLT uptake early after therapy.\"},{\"question\":\"How does [18F]FLT-PET compare with [18F]FDG-PET for response assessment?\",\"answer\":\"Two comparative studies with 58 patients showed that post-therapy [18F]FLT-PET uptake was significantly lower than post-therapy [18F]FDG uptake in HNC patients.\"}]","Added value of 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography for response assessment in patients with head and neck cancer - a systematic review | PDF",1790179170,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3e658126f5b1801646d41c4faf8d6e8.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/182516c70fa0801e8863f94f20cd5ae3.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98fec9f1522fa856f1af491508cd484f.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efa9b384158dff819e5b1376ebd4b024.webp",980,1306]